Literature DB >> 27273865

KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors.

Jamie L McCall1, Drew Gehring1, Beth K Clymer1, Kurt W Fisher1, Binita Das1, David L Kelly1, Hyunseok Kim2, Michael A White2, Robert E Lewis3.   

Abstract

Identification and characterization of survival pathways active in tumor cells but absent in normal tissues provide opportunities to develop effective anticancer therapies with reduced toxicity to the patient. We show here that, like kinase suppressor of Ras 1 (KSR1), EPH (erythropoietin-producing hepatocellular carcinoma) receptor B4 (EPHB4) is aberrantly overexpressed in human colon tumor cell lines and selectively required for their survival. KSR1 and EPHB4 support tumor cell survival by promoting the expression of downstream targets, Myc and the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1β (PGC1β). While KSR1 promotes the aberrant expression of Myc and the PGC1β protein via a posttranscriptional mechanism, EPHB4 has a greater effect on Myc and PGC1β expression via its ability to elevate mRNA levels. Subsequent analysis of the posttranscriptional regulation demonstrated that KSR1 promotes the translation of Myc protein. These findings reveal novel KSR1- and EPHB4-dependent signaling pathways supporting the survival of colorectal cancer cells through regulation of Myc and PGC1β, suggesting that inhibition of KSR1 or EPHB4 effectors may lead to selective toxicity in colorectal tumors.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27273865      PMCID: PMC4985931          DOI: 10.1128/MCB.00087-16

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  87 in total

1.  Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.

Authors:  W S Samowitz; K Curtin; D Schaffer; M Robertson; M Leppert; M L Slattery
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-11       Impact factor: 4.254

Review 2.  Regulation of angiogenesis by Eph-ephrin interactions.

Authors:  Sanne Kuijper; Christopher J Turner; Ralf H Adams
Journal:  Trends Cardiovasc Med       Date:  2007-07       Impact factor: 6.677

3.  Using functional signature ontology (FUSION) to identify mechanisms of action for natural products.

Authors:  Malia B Potts; Hyun Seok Kim; Kurt W Fisher; Youcai Hu; Yazmin P Carrasco; Gamze Betul Bulut; Yi-Hung Ou; Mireya L Herrera-Herrera; Federico Cubillos; Saurabh Mendiratta; Guanghua Xiao; Matan Hofree; Trey Ideker; Yang Xie; Lily Jun-shen Huang; Robert E Lewis; John B MacMillan; Michael A White
Journal:  Sci Signal       Date:  2013-10-15       Impact factor: 8.192

4.  Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer.

Authors:  M Li; Z W Zhao; Y Zhang; Y Xin
Journal:  Dig Dis Sci       Date:  2010-08-05       Impact factor: 3.199

5.  EphB4 expression and biological significance in prostate cancer.

Authors:  Guangbin Xia; S Ram Kumar; Rizwan Masood; Sutao Zhu; Ramchandra Reddy; Valery Krasnoperov; David I Quinn; Susan M Henshall; Robert L Sutherland; Jacek K Pinski; Siamak Daneshmand; Maurizio Buscarini; John P Stein; Chen Zhong; Daniel Broek; Pradip Roy-Burman; Parkash S Gill
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

6.  c-Myc is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium.

Authors:  Michael D Bettess; Nicole Dubois; Mark J Murphy; Christelle Dubey; Catherine Roger; Sylvie Robine; Andreas Trumpp
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  Identification of c-MYC as a target of the APC pathway.

Authors:  T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1998-09-04       Impact factor: 47.728

8.  Expression of EphB4 in head and neck squamous cell carcinoma.

Authors:  Uttam K Sinha; Ajay Kundra; Pierluigi Scalia; Diane L Smith; Behdad Parsa; Rizwan Masood; Parkash S Gill
Journal:  Ear Nose Throat J       Date:  2003-11       Impact factor: 1.697

9.  Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF beta-receptor.

Authors:  A Sorkin; B Westermark; C H Heldin; L Claesson-Welsh
Journal:  J Cell Biol       Date:  1991-02       Impact factor: 10.539

10.  125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts.

Authors:  G Carpenter; S Cohen
Journal:  J Cell Biol       Date:  1976-10       Impact factor: 10.539

View more
  14 in total

1.  EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.

Authors:  Akil A Merchant; Aparna Jorapur; Amy McManus; Ren Liu; Valery Krasnoperov; Parvesh Chaudhry; Mohan Singh; Lisa Harton; Mary Agajanian; Miriam Kim; Timothy J Triche; Brian J Druker; Jeffrey W Tyner; Parkash S Gill
Journal:  Blood Adv       Date:  2017-08-28

Review 2.  KSR as a therapeutic target for Ras-dependent cancers.

Authors:  Beth K Neilsen; Danielle E Frodyma; Robert E Lewis; Kurt W Fisher
Journal:  Expert Opin Ther Targets       Date:  2017-04-07       Impact factor: 6.902

3.  Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.

Authors:  Chaohao Li; Nadia A Lanman; Yifan Kong; Daheng He; Fengyi Mao; Elia Farah; Yanquan Zhang; Jinghui Liu; Chi Wang; Qiou Wei; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

4.  KSR1- and ERK-dependent translational regulation of the epithelial-to-mesenchymal transition.

Authors:  Chaitra Rao; Danielle E Frodyma; Siddesh Southekal; Robert A Svoboda; Adrian R Black; Chittibabu Guda; Tomohiro Mizutani; Hans Clevers; Keith R Johnson; Kurt W Fisher; Robert E Lewis
Journal:  Elife       Date:  2021-05-10       Impact factor: 8.140

5.  A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells.

Authors:  Binita Das; Beth K Neilsen; Kurt W Fisher; Drew Gehring; Youcai Hu; Deanna J Volle; Hyun Seok Kim; Jamie L McCall; David L Kelly; John B MacMillan; Michael A White; Robert E Lewis
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

6.  ERK-mediated TIMELESS expression suppresses G2/M arrest in colon cancer cells.

Authors:  Beth K Neilsen; Danielle E Frodyma; Jamie L McCall; Kurt W Fisher; Robert E Lewis
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

7.  EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.

Authors:  Vinay Sagar; Rajita Vatapalli; Barbara Lysy; Sahithi Pamarthy; Jonathan F Anker; Yara Rodriguez; Huiying Han; Kenji Unno; Walter M Stadler; William J Catalona; Maha Hussain; Parkash S Gill; Sarki A Abdulkadir
Journal:  Cell Death Dis       Date:  2019-10-22       Impact factor: 8.469

Review 8.  Coordinating ERK signaling via the molecular scaffold Kinase Suppressor of Ras.

Authors:  Danielle Frodyma; Beth Neilsen; Diane Costanzo-Garvey; Kurt Fisher; Robert Lewis
Journal:  F1000Res       Date:  2017-08-31

9.  Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors.

Authors:  Songlin Li; Yuan Yuan; He Xiao; Jiajia Dai; Yunfei Ye; Qin Zhang; Zhimin Zhang; Yuhan Jiang; Jia Luo; Jing Hu; Chuan Chen; Ge Wang
Journal:  Clin Epigenetics       Date:  2019-03-04       Impact factor: 6.551

10.  Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma.

Authors:  Michael DiPrima; Dunrui Wang; Alix Tröster; Dragan Maric; Nekane Terrades-Garcia; Taekyu Ha; Hyeongil Kwak; David Sanchez-Martin; Denis Kudlinzki; Harald Schwalbe; Giovanna Tosato
Journal:  Mol Oncol       Date:  2019-10-23       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.